Marcus Vale: Astellas just had a very good news cycle. OPTION-VMS results drop at ENDO 2026 in Chicago, New York Post picks it up same day, June 14th — fezolinetant reduces hot flashes, reduces anxiety, reduces depression. That's a big expansion from what the FDA actually approved it for.
Ben Okonkwo: Now — approved for vasomotor symptoms. Hot flashes, night sweats. That's what the SKYLIGHT trials measured. OPTION-VMS is something different.
Marcus Vale: Different how? It's the same drug.
Ben Okonkwo: Different evidence architecture. SKYLIGHT 1 was a randomized controlled trial. OPTION-VMS is the first real-world study — observational, not randomized, and industry-sponsored by Astellas. Pauline Maki at University of Illinois Chicago is the lead researcher. She told the Post herself: the magnitude of the mood effect surprised her. Her words — 'I didn't anticipate it, though, because it's a hard level of symptoms to improve.' That's a scientist flagging uncertainty, not confirming a mechanism.
Marcus Vale: Hold on — so the mechanism for the mood improvement isn't established?
Ben Okonkwo: Not directly. NK3 receptor antagonism — which is how fezolinetant and elinzanetant both work — blocks neurokinin B from binding to KNDy neurons in the hypothalamus. That normalizes thermoregulation. But anxiety and depression? The plausible explanation is indirect: you stop the hot flashes, women sleep, sleep improves mood. That's a different claim than the drug acting on mood pathways directly. And those two explanations have very different commercial and clinical implications.
Marcus Vale: Okay but does the distinction matter to Astellas? If the outcome is real — even if it's downstream of symptom relief — that's still label-expansion territory.
Ben Okonkwo: It matters to regulators. And it matters to the women taking it. You can't make a psychiatric indication claim on one observational study. That's not a high bar, Marcus — that's the floor.
Marcus Vale: Fair. But NICE recommended fezolinetant — Veoza, they call it — for roughly 500,000 UK patients back in March 2026. TA1143. And NICE kept HRT as first-line in the same guidance. That's the part I can't square. You don't recommend something for half a million people as second-line without signaling it's mainstream.
Ben Okonkwo: The 500,000 estimate is specifically women for whom HRT is unsuitable. That's the carve-out — cancer survivors, women with clot risk. That's not incoherence, that's a defined contraindicated population.
Marcus Vale: But Lee Shulman at Northwestern is already calling it first-line mainstream for all women. That's a gap between what NICE says and what clinicians are doing.
Ben Okonkwo: Hm. And that gap is exactly where the tumor risk signal becomes uncomfortable. Because the women who need fezolinetant most — cancer survivors, hormone-contraindicated — are also the population flagged in the 2026 paper. Felice Gersh specifically raised that paper, pubmed 42137787. Possible non-benign tumor signal. Not confirmed causation, but in the exact cohort this drug was designed to serve.
Marcus Vale: That's the commercial tragedy, right? Astellas builds for an unmet need — women who can't do HRT — and the safety signal shows up there first.
Ben Okonkwo: And the NK3 pathway isn't just thermoregulation. Neurokinin B, kisspeptin signaling — it touches neuroendocrine and immune pathways. We don't have three-to-five year follow-up data for fezolinetant or elinzanetant. Both are post-approval. The FDA approved fezolinetant in May 2023, elinzanetant only got approved in 2025. That's a very short safety window to be positioning this as a mainstream first-line option.
Marcus Vale: Meanwhile HRT demand is surging. Pharmac in New Zealand had to ration supply. So you have a rising HRT tide and Astellas trying to capture first-line positioning before body-identical hormones fully reclaim the narrative.
Ben Okonkwo: And the pooled HRT breast cancer data actually helps HRT here — 4.5 million women across 34 studies, published March 2026 in AJMC. The cancer risk is concentrated in estrogen-progestin combinations. Estrogen-only looks neutral or potentially protective. So the fear that drove women away from HRT is more targeted than people realized.
Marcus Vale: Wait — so the drug that was supposed to be the safe non-hormonal alternative has a tumor signal, and the hormone therapy it was replacing is getting cleared of some of its cancer risk at the same time?
Ben Okonkwo: That's approximately where we are. The safety narratives crossed in 2026. Whether the tumor signal from fezolinetant holds in larger populations — that's the question. If it does, fezolinetant stays specialist-use. If it doesn't, Astellas has a genuine mass-market drug. We just don't have the data yet.
Marcus Vale: And in the meantime Lee Shulman is out there saying first-line for everyone while NICE says second-line and the mood claim is sitting on one industry-sponsored observational study. That's a lot of weight on very thin ice.
Marcus Vale: Honestly the prescribing landscape looks like a mess. Because if the tumor signal firms up and fezolinetant gets boxed or pulled back, every woman who switched off HRT because her doctor was pattern-matching to 'non-hormonal equals safer' — she's now in a gap. No HRT, no fezolinetant, and her hot flashes are back. That's the commercial and clinical consequence nobody's modeling right now.
Ben Okonkwo: And the mood benefit disappears with it. Because that's not a separate drug — it's the same mechanism, same compound. If fezolinetant gets restricted, you don't get to keep the anxiolytic claim. It all moves together.
Marcus Vale: So the real question is whether Astellas has three years before the long-term data lands, or two. Because the positioning decisions are being made right now — and the window to walk back 'first-line for everyone' gets a lot smaller the more women are already on it.
